The results of CAR-T cells modified with CRISPR Therapeutics' gene editing technology (CRSP.US) according to GlobalData analysts represent a significant step in cancer treatment. Following the recent positive results of Moderna's vaccine and Merck's immunotherapy, came positive news reporting the first gene editing successes against cancer cells. Shares of CRISPR Therapeutics are trading slightly higher:
- The first patient of the initial phase of the TvT CAR7 trial at UCL Great Ormond Street Insititute of Child Health (GOSH), for the treatment of pediatric acute lymphoblastic leukemia has fought off cancer cells (remission);
Oncology & Hematology analysts at medical market analysis firm GlobalData have already commented on the topic:
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile app"Although the GOSH TvT CAR7 trial has so far produced excellent results in only one patient, this is a significant development - not only for patients with T-ALL (a type of lymphoblastic leukemia) but also for patients with other cancers. If a target can be identified, the CRISPR technology could be used in other blood system diseases besides T-ALL. However, this will take some time, and GlobalData does not forecast the release of a commercial CAR-T product for T-ALL in the near future."
- The CAR-T cells used in this study, named BE CAR-7, were donated by healthy donors and modified by the company's CRISPR to induce selective toxicity against antigen-positive tumor cells. Previous medical and academic trials have yielded mixed results. Effective therapies that improve patients' overall survival even after relapse.
Crispr Therapeutics (CRSP.US) shares, D1 interval. The price of the company's stock is drawing bullish higher lows and struggling to get above the SMA100 (black line). Source: xStation5
